BioCentury
ARTICLE | Clinical News

Catabasis reports DMD candidate slowed disease progression

October 4, 2017 8:57 AM UTC

Catabasis Pharmaceuticals Inc. (NASDAQ:CATB) gained $0.20 to $3.03 on Wednesday after it said results from the open-label extension of the Phase II MoveDMD trial showed edasalonexent (CAT-1004) slowed disease progression in boys aged 4-7 with Duchenne muscular dystrophy. The company plans to start a registrational Phase III trial in 1H18 in pediatric patients with DMD regardless of mutation type.

Edasalonexent is a conjugate of salicylate and docosahexaenoic acid (DHA) that inhibits activated nuclear factor of kappa light polypeptide gene enhancer in B cells 1 (NF-kB; NFKB1; p105; p50). Catabasis said the therapy significantly improved muscle inflammation at 12 weeks and at last observation compared to a mean 39-week control period prior to treatment, as measured by MRI of lower leg muscles (p<0.05). Edasalonexent also significantly decreased levels of four muscle enzymes compared to baseline at 12 weeks (p<0.05)...